Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1970 1
1978 3
1979 1
1980 1
1981 2
1982 2
1983 4
1984 4
1985 1
1986 3
1987 3
1988 1
1989 3
1990 6
1991 3
1992 9
1993 3
1994 5
1995 5
1996 4
1997 6
1998 8
1999 3
2000 6
2001 7
2002 3
2003 5
2004 3
2005 5
2006 7
2007 8
2008 7
2009 13
2010 7
2011 10
2012 6
2013 4
2014 5
2015 5
2016 7
2017 5
2018 5
2020 3
2021 1
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Stewart AK, et al. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482145 Free article. Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
[Waldenström macroglobulinemia].
Telek B, Batár P, Váróczy L, Gergely L, Rejtő L, Szász R, Miltényi Z, Simon Z, Udvardy M, Illés A. Telek B, et al. Among authors: udvardy m. Orv Hetil. 2013 Dec 1;154(50):1970-4. doi: 10.1556/OH.2013.29776. Orv Hetil. 2013. PMID: 24317355 Hungarian.
[Recommendation: Hodgkin disease].
Illés A, Molnár Z, Udvardy M. Illés A, et al. Among authors: udvardy m. Magy Onkol. 2001;45(1):53-57. Magy Onkol. 2001. PMID: 12050729 Free article. Hungarian. No abstract available.
Erratum.
Cattell M, Udvardy M. Cattell M, et al. Among authors: udvardy m. J Cross Cult Gerontol. 1993 Jan;8(1):91. doi: 10.1007/BF00973803. J Cross Cult Gerontol. 1993. PMID: 24389758 No abstract available.
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Ludwig H, et al. Among authors: udvardy m. Oncologist. 2011;16(4):388-403. doi: 10.1634/theoncologist.2010-0386. Epub 2011 Mar 26. Oncologist. 2011. PMID: 21441574 Free PMC article. Review.
[Chronic myeloid leukemia].
Udvardy M. Udvardy M. Orv Hetil. 2005 Feb 6;146(6):243-7. Orv Hetil. 2005. PMID: 15779811 Review. Hungarian.
199 results